Our work, pioneered by Dr. Chenzhen Zhang (read the paper [HERE]), showcased CPC’s capability to enhance contrast agent delivery for CT imaging purposes. The patented platform provided a high-quality imaging modality at a significantly lower dosage compared to the conventional approach.